(Gestational Trophoblastic Tumor) Is Anti-PD-1 Camrelizumab Plus Apatinib Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- November 2, 2021
- 1 min read
On October 5, 2021, Dr. Hongyan Cheng and colleagues from Peking Union Medical College Hospital published results in The Lancet from a Phase 2 clinical trial evaluating the efficacy and safety of the anti-PD-1 antibody camrelizumab combined with apatinib in patients with high-risk, chemotherapy-resistant, recurrent gestational trophoblastic tumors (GTT).
This Phase 2 trial was a single-arm, open-label study with a 4-week treatment cycle. Patients with high-risk, chemotherapy-resistant, recurrent GTT received camrelizumab (200 mg on days 1 and 15) plus apatinib (250 mg once daily) until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR).
Results at median follow-up of 18.5 months:
- Objective response rate (ORR): 55%
- Complete response (CR): 50%
Safety:
Grade 3 or higher adverse events observed in most patients included hypertension (25%, N=5), skin abnormalities (20%, N=4), and neutropenia (10%, N=2). No higher-grade adverse events were confirmed.
Conclusion: Based on the Phase 2 trial results, Dr. Cheng and colleagues concluded that camrelizumab plus apatinib demonstrated meaningful anti-tumor activity with acceptable tolerability in high-risk, chemotherapy-resistant, recurrent GTT patients, and may represent a new treatment option for this patient population.
Source: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00460-5/fulltext
-
Immunotherapy
-
Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4